Rüther E, Benkert O, Eckmann F, Eckmann I, Grohmann R, Helmchen H, Hippius H, Müller-Oerlinghausen B, Poser W, Schmidt L, Stille G, Strauss A, Uberla K
Arzneimittelforschung. 1980;30(8):1181-3.
The Study Group for Drug Surveillance in Psychiatry (AMUP) has been working since July 1978 as a task force group of the "Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie" (AGNP). A protocol was designed for the initiation of drug monitoring in psychiatric hospitals. With support of the Bundesgesundheitsamt, Berlin, the first part of this project was started as a practicability study in the psychiatric hospitals of the Universities of Berlin, Göttingen, and Munich and in the municipal hospital of Schleswig. The study includes 7650 in-patients. It is based on the following methods: intensive drug monitoring, organized spontaneous monitoring of adverse drug reactions and registration of drug applications. This drug monitoring system in psychiatry will be expanded to other psychiatric hospitals, and eventually to out-patient clinics as well as private practices within the next two years.
精神科药物监测研究小组（AMUP）自1978年7月起作为“神经精神药理学与药物精神病学工作小组”（AGNP）的一个特别工作组开展工作。已设计了一项在精神病医院启动药物监测的方案。在柏林联邦卫生局的支持下，该项目的第一部分作为一项可行性研究在柏林、哥廷根和慕尼黑大学的精神病医院以及石勒苏益格市立医院开展。该研究包括7650名住院患者。它基于以下方法：强化药物监测、有组织的药物不良反应自发监测以及药物应用登记。精神科的这种药物监测系统将在未来两年内扩展到其他精神病医院，并最终扩展到门诊诊所及私人诊所。
